Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report

Zoysa, Madushka De; Nakamaru, Nicole A.; Kaiser, Samantha B.; Ciccone, Marcia A.; Muderspach, Laila I.; Matsuo, Koji

doi:10.1016/j.gore.2017.12.002

Cited by 4 publications

(9 citation statements)

References 16 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It typically occurs more than 10 min after the first drip of the 11th to 20th course of the drug (Table 3, Figures 1 and 2). This finding was compatible with numerous previous reports about carboplatin hypersensitivity of any grade 3,7–9 . However, the interval between the previous carboplatin administration and severe anaphylaxis remains controversial.…”

Section: Discussionsupporting

confidence: 92%

“…Various protocols have been advocated for patients who experience carboplatin hypersensitivity 17,18 . However, re‐administration of the trigger medication that caused severe anaphylaxis cannot be justified 4,7,19 . Interestingly, only gynecological patients experienced carboplatin‐induced severe anaphylaxis in our study, despite carboplatin being commonly used for a variety of cancers.…”

Section: Discussionmentioning

confidence: 80%

“…Paclitaxel re‐administration may be considered once mild symptoms subside 8,20 . However, paclitaxel re‐administration after severe anaphylaxis seems too risky 4,7,19 . Polyethylated castor oil solvent of paclitaxel is known to directly cause hypersensitivity via the non‐IgE mechanism 5,21,22 .…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, severe anaphylaxis should be paid careful attention. However, few studies have focused on chemotherapy‐induced severe anaphylaxis, except for case reports 7 . Despite the recommended use of dexamethasone and H1/H2 antihistamine prophylactic pretreatment prior to chemotherapies, 5,8 some patients still experience severe anaphylaxis.…”

Section: Introductionmentioning

confidence: 99%

“…However, few studies have focused on chemotherapy‐induced severe anaphylaxis, except for case reports. 7 Despite the recommended use of dexamethasone and H1/H2 antihistamine prophylactic pretreatment prior to chemotherapies, 5 , 8 some patients still experience severe anaphylaxis. Therefore, we need to know the incidence and risk factors of severe anaphylaxis caused by intravenous anti‐cancer drugs to prepare for acute‐onset critical events and to design novel regimens.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Severe anaphylaxis caused by intravenous anti‐cancer drugs

et al. 2021

View full text Add to dashboard Cite

Background The incidence and risk factors of severe anaphylaxis by intravenous anti‐cancer drugs are unclear, whereas those of milder reactions have been reported. Study Design Electronic medical charts of cancer patients who have undergone intravenous chemotherapy between January 2013 and October 2020 in a university hospital were retrospectively reviewed. Non‐epithelial malignancies were also included in the analysis. "Severe anaphylaxis" was judged using Brown's criteria: typical presentation of anaphylaxis and one or more of hypoxia, shock, and neurologic compromise. (UMIN000042887). Results Among 5584 patients (2964 males [53.1%], 2620 females [46.9%], median age 66 years), 88,200 person‐day anti‐cancer drug administrations were performed intravenously, and 27 severe anaphylaxes were observed. The causative drugs included carboplatin (14 cases), paclitaxel (9 cases), and cisplatin, docetaxel, trastuzumab, and cetuximab (1 case each). The person‐based lifetime incidence of severe anaphylaxis for patients who received at least one intravenous chemotherapy was 0.48% (27/5584, 95% confidence interval (CI) 0.30%–0.67%) and the administration‐based incidence was 0.031% (27/88,200, 95% CI 0.019%–0.043%). Among 124 patients who received at least 10 carboplatin administrations, 10 patients experienced carboplatin‐induced severe anaphylaxis (10/124, 8.1%, 95% CI 3.0%–13.1%). Carboplatin caused severe anaphylaxis after at least 9‐min interval since the drip started. Thirteen out of 14 patients experienced carboplatin‐induced severe anaphylaxis within a 75‐day interval from the previous treatment. Paclitaxel infusion caused severe anaphylaxis after a median of 5 min after the first drip of the day at a life‐long incidence of 0.93% (9/968, 95% CI 0.27%–1.59%). Conclusion We elucidated the high‐risk settings of chemotherapy‐induced severe anaphylaxis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 80%